![ChampionX Corporation](/common/images/company/TG_X9P.png)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Canaccord Genuity 44th Annual Growth...
Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC screening and is commercially available in U.S...
Largest study to date evaluating MRD detection using tissue-free approach demonstrates 81% longitudinal sensitivity for recurrence in stage II or higher colon cancer Data demonstrate potential...
FDA approval announced earlier this week makes Shield first blood test that is approved for primary screening of colorectal cancer and meets coverage requirements for Medicare reimbursement...
Research Study Accepted for Publication Demonstrates Efficacy of Blood-Based Tests for CRC Screening Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the...
Shieldは血液検査としてメディケア・カバレッジにおける性能要件を満たしており、大腸がんの一次スクリーニング検査オプションとして初のFDA承認 容易で利便性の高い快適なスクリーニング検査オプションを提供...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.